JPH11507935A - リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 - Google Patents
リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物Info
- Publication number
- JPH11507935A JPH11507935A JP9503581A JP50358197A JPH11507935A JP H11507935 A JPH11507935 A JP H11507935A JP 9503581 A JP9503581 A JP 9503581A JP 50358197 A JP50358197 A JP 50358197A JP H11507935 A JPH11507935 A JP H11507935A
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- polysaccharide
- vaccine according
- adsorbed
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000000427 antigen Substances 0.000 title claims abstract description 23
- 102000036639 antigens Human genes 0.000 title claims abstract description 23
- 108091007433 antigens Proteins 0.000 title claims abstract description 23
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 title claims abstract description 16
- 229920001282 polysaccharide Polymers 0.000 title claims description 30
- 239000005017 polysaccharide Substances 0.000 title claims description 30
- 150000004676 glycans Chemical class 0.000 title claims description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 3
- 206010013023 diphtheria Diseases 0.000 claims description 13
- 229960000814 tetanus toxoid Drugs 0.000 claims description 11
- 102000014914 Carrier Proteins Human genes 0.000 claims description 10
- 108010078791 Carrier Proteins Proteins 0.000 claims description 10
- 206010043376 Tetanus Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 241000606768 Haemophilus influenzae Species 0.000 claims description 7
- 208000002672 hepatitis B Diseases 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- 241000709721 Hepatovirus A Species 0.000 claims description 4
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 208000037798 influenza B Diseases 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 101710116435 Outer membrane protein Proteins 0.000 claims description 3
- 208000000474 Poliomyelitis Diseases 0.000 claims description 3
- 239000008215 water for injection Substances 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims 2
- 206010061190 Haemophilus infection Diseases 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 13
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 229940031348 multivalent vaccine Drugs 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000009739 binding Methods 0.000 description 6
- 229960004443 hemophilus influenzae b vaccines Drugs 0.000 description 6
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- -1 1-cyano-4-dimethylaminopyridinium tetrafluoroborate Chemical compound 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229910017119 AlPO Inorganic materials 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- 229940031670 conjugate vaccine Drugs 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229940029583 inactivated polio vaccine Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229940124914 Havrix Drugs 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000004643 cyanate ester Substances 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 229940045808 haemophilus influenzae type b Drugs 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229940124884 Engerix-B Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229940124915 Infanrix Drugs 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940124909 PedvaxHIB Drugs 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960005097 diphtheria vaccines Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. リン酸アルミニウム上へ吸着したポリサッカライド結合抗原からなるワク チン組成物。 2. 抗原が担体蛋白質とのヘモフィルスインフルエンザ(Haemophilius influ enzae)B型結合体由来の莢膜ポリサッカライドである請求項1に記載のワクチ ン。 3. 担体をジフテリア(Diphtheria)トキソイド、ジフテリアCRM197蛋白 質、髄膜炎菌外膜蛋白質および破傷風トキソイドからなる群から選択する請求項 1または2に記載のワクチン。 4. 担体蛋白質が破傷風トキソイドである請求項1、2または3に記載のワク チン。 5. ポリサッカライド対蛋白質の比率が1:0.3〜1:2(重量:重量)であ る請求項1〜4のいずれか1つに記載のワクチン。 6. ヘモフィルスインフルエンザB型以外の病原体に対する保護を提供するた めに、少なくとも1種の他の成分を含有する請求項1〜5のいずれかに記載のワ クチン。 7. 他の成分がA型肝炎ウイルス、ジフテリア、破傷風、百日咳、B型肝炎お よびポリオの1つに対する保護を提供する抗原群から選択される請求項1〜6の いずれかに記載のワクチン。 8. 吸着した結合体が凍結乾燥している請求項1〜7のいずれか1つに記載の ワクチン。 9. 吸着した結合体が注射用水に懸濁している請求項1〜7のいずれかに記載 のワクチン。 10. 請求項8に記載の凍結乾燥ワクチンのコンテナと、別の病原体に対する ワクチンを含む別のコンテナとからなるキット。 11. ポリサッカライド抗原を蛋白質担体と結合させ、該抗原をリン酸アルミ ニウム上へ吸着させることを特徴とする請求項1〜6に記載のワクチンの製造方 法。 12. 医薬における用途としての請求項1〜9のいずれか1つに記載のワクチ ン組成物。 13. ヘモフィルスインフルエンザb型感染に罹患した、または感染しやすい 患者の治療方法であって、安全で有効量の請求項1〜9のいずれか1つに記載の ワクチン組成物を投与することからなる方法。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9512827.8A GB9512827D0 (en) | 1995-06-23 | 1995-06-23 | Vaccines |
GB9512827.8 | 1995-06-23 | ||
GBGB9513443.3A GB9513443D0 (en) | 1995-07-01 | 1995-07-01 | Vaccines |
GB9513443.3 | 1995-07-01 | ||
GB9525657.4 | 1995-12-15 | ||
GBGB9525657.4A GB9525657D0 (en) | 1995-12-15 | 1995-12-15 | Vaccines |
GB9606032.2 | 1996-03-22 | ||
GBGB9606032.2A GB9606032D0 (en) | 1996-03-22 | 1996-03-22 | Vaccines |
PCT/EP1996/002690 WO1997000697A1 (en) | 1995-06-23 | 1996-06-19 | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008033301A Division JP2008120833A (ja) | 1995-06-23 | 2008-02-14 | リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11507935A true JPH11507935A (ja) | 1999-07-13 |
JP4850987B2 JP4850987B2 (ja) | 2012-01-11 |
Family
ID=27451299
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50358197A Expired - Lifetime JP4850987B2 (ja) | 1995-06-23 | 1996-06-19 | リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 |
JP2008033301A Pending JP2008120833A (ja) | 1995-06-23 | 2008-02-14 | リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008033301A Pending JP2008120833A (ja) | 1995-06-23 | 2008-02-14 | リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 |
Country Status (36)
Country | Link |
---|---|
EP (2) | EP0833662B2 (ja) |
JP (2) | JP4850987B2 (ja) |
KR (1) | KR100425929B1 (ja) |
CN (1) | CN1146444C (ja) |
AP (1) | AP812A (ja) |
AR (1) | AR003006A1 (ja) |
AT (2) | ATE199831T1 (ja) |
AU (1) | AU696338B2 (ja) |
BG (1) | BG62720B1 (ja) |
BR (1) | BRPI9609414B8 (ja) |
CA (1) | CA2222455C (ja) |
CY (1) | CY2297B1 (ja) |
CZ (1) | CZ288908B6 (ja) |
DE (2) | DE69637950D1 (ja) |
DK (2) | DK0833662T4 (ja) |
DZ (1) | DZ2055A1 (ja) |
EA (1) | EA199700413A1 (ja) |
EG (1) | EG25924A (ja) |
ES (2) | ES2325301T3 (ja) |
GR (1) | GR3036088T3 (ja) |
HK (2) | HK1009764A1 (ja) |
HU (1) | HU224514B1 (ja) |
IL (1) | IL122588A (ja) |
MA (1) | MA23918A1 (ja) |
MY (1) | MY114786A (ja) |
NO (1) | NO325169B1 (ja) |
NZ (1) | NZ312132A (ja) |
OA (1) | OA10646A (ja) |
PE (1) | PE11298A1 (ja) |
PL (1) | PL184872B1 (ja) |
PT (2) | PT1082965E (ja) |
SI (2) | SI0833662T2 (ja) |
SK (1) | SK176197A3 (ja) |
TR (1) | TR199701682T1 (ja) |
TW (1) | TW467746B (ja) |
WO (1) | WO1997000697A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004501873A (ja) * | 2000-06-29 | 2004-01-22 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
JP2006512406A (ja) * | 2002-11-01 | 2006-04-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原組成物 |
JP2010532985A (ja) * | 2007-07-10 | 2010-10-21 | サノフィ・パスツール | ヘモフィルス・インフルエンザb型菌用の培養培地 |
JP2012051943A (ja) * | 2001-04-03 | 2012-03-15 | Glaxosmithkline Biologicals Sa | ワクチン組成物 |
JP2012520849A (ja) * | 2009-03-19 | 2012-09-10 | インターベツト・インターナシヨナル・ベー・ベー | 動物の所定の群れに対して投与するためのワクチンのその場(insitu)構成 |
JP2012521402A (ja) * | 2009-03-24 | 2012-09-13 | ノバルティス アーゲー | アジュバント添加した髄膜炎菌h因子結合タンパク質 |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ283910B6 (cs) | 1992-05-23 | 1998-07-15 | Smithkline Beecham Biologicals (S.A.) | Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku |
US6355450B1 (en) | 1995-04-21 | 2002-03-12 | Human Genome Sciences, Inc. | Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof |
US6468765B1 (en) | 1995-04-21 | 2002-10-22 | Human Genome Sciences, Inc. | Selected Haemophilus influenzae Rd polynucleotides and polypeptides |
US6696065B1 (en) | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
EP0833662B2 (en) * | 1995-06-23 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
BRPI9710460B8 (pt) * | 1996-07-02 | 2021-05-25 | Aventis Pasteur | composição imunogênica multi-valente e composição de vacina |
GB9806456D0 (en) * | 1998-03-25 | 1998-05-27 | Smithkline Beecham Biolog | Vaccine composition |
EP1126876B1 (en) | 1998-10-16 | 2007-03-21 | GlaxoSmithKline Biologicals S.A. | Adjuvant systems and vaccines |
US6585973B1 (en) | 1998-10-29 | 2003-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method for preparing solid phase conjugated vaccine |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
JP2005504718A (ja) | 2001-01-23 | 2005-02-17 | アヴェンティス パストゥール | 多価髄膜炎菌多糖−タンパク質複合ワクチン |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
AU2003274511B2 (en) | 2002-10-11 | 2009-06-04 | Glaxosmithkline Biologicals S.A. | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CN102302776B (zh) | 2003-01-30 | 2014-06-18 | 诺华疫苗和诊断有限公司 | 抗多种脑膜炎球菌血清组的可注射性疫苗 |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
EP1667712B1 (en) * | 2003-10-02 | 2010-07-21 | GlaxoSmithKline Biologicals S.A. | B. pertussis antigens and use thereof in vaccination |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
BRPI0415025A (pt) | 2003-10-02 | 2006-12-12 | Chiron Srl | vacinas lìquidas para sorogrupos meningocócicos múltiplos |
GB0405787D0 (en) * | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
RU2379052C2 (ru) | 2004-04-30 | 2010-01-20 | Чирон С.Р.Л. | Вакцинация менингококковыми конъюгатами |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
GB0505996D0 (en) | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Fermentation process |
SG175456A1 (en) | 2005-04-18 | 2011-11-28 | Novartis Vaccines & Diagnostic | Expressing hepatitis b virus surface antigen for vaccine preparation |
US8329184B2 (en) | 2005-06-27 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Process for manufacturing vaccines |
GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
WO2007111940A2 (en) | 2006-03-22 | 2007-10-04 | Novartis Ag | Regimens for immunisation with meningococcal conjugates |
US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
EA016417B1 (ru) | 2006-09-07 | 2012-04-30 | Глаксосмитклайн Байолоджикалс С.А. | Способ получения вакцины |
AR066376A1 (es) | 2007-05-02 | 2009-08-12 | Glaxosmithkline Biolog Sa | Vacuna |
AU2008259423A1 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
GB0917647D0 (en) | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
RU2013136397A (ru) | 2011-01-05 | 2015-02-10 | Бхарат Байотек Интернэшнл Лимитед | Комбинированная семивалентная вакцина |
GB201105981D0 (en) | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
PT2809343T (pt) | 2012-02-01 | 2017-12-21 | Glaxosmithkline Biologicals Sa | Processo de fermentação |
WO2014009971A2 (en) * | 2012-07-07 | 2014-01-16 | Bharat Biotech International Limited | Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
US20140037680A1 (en) | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
CA2886938A1 (en) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
SG11201600709TA (en) | 2013-08-05 | 2016-02-26 | Glaxosmithkline Biolog Sa | Combination immunogenic compositions |
WO2018156465A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier |
EA202090316A1 (ru) | 2017-07-18 | 2020-12-08 | Серум Инститьют Оф Индия Пвт Лтд. | Иммуногенная композиция с повышенной стабильностью, усиленной иммуногенностью и уменьшенной реактогенностью и способ ее получения |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
US11433129B2 (en) | 2019-05-20 | 2022-09-06 | Soligenix, Inc. | Compositions and methods of manufacturing trivalent filovirus vaccines |
CN111658617A (zh) * | 2019-10-14 | 2020-09-15 | 四川大学 | 一种含铝佐剂疫苗的冻干制剂及其制备方法和用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
IL98715A0 (en) * | 1990-08-13 | 1992-07-15 | American Cyanamid Co | Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
DE69333107T2 (de) | 1992-02-11 | 2004-01-29 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
CZ283910B6 (cs) | 1992-05-23 | 1998-07-15 | Smithkline Beecham Biologicals (S.A.) | Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku |
SG47725A1 (en) | 1992-10-27 | 1998-04-17 | American Cyanamid Co | Combination pediatric vaccine with enhanced immunogenicity of each vaccine component |
EP0833662B2 (en) * | 1995-06-23 | 2011-01-26 | SmithKline Beecham Biologicals S.A. | A vaccine composition comprsing a Haemophilus influenzae B polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
-
1996
- 1996-06-19 EP EP96922871A patent/EP0833662B2/en not_active Expired - Lifetime
- 1996-06-19 SI SI9630310T patent/SI0833662T2/sl unknown
- 1996-06-19 EP EP00203874A patent/EP1082965B1/en not_active Expired - Lifetime
- 1996-06-19 DK DK96922871.7T patent/DK0833662T4/da active
- 1996-06-19 PT PT00203874T patent/PT1082965E/pt unknown
- 1996-06-19 CZ CZ19974189A patent/CZ288908B6/cs not_active IP Right Cessation
- 1996-06-19 DK DK00203874T patent/DK1082965T3/da active
- 1996-06-19 AP APAP/P/1997/001159A patent/AP812A/en active
- 1996-06-19 HU HU9900061A patent/HU224514B1/hu active IP Right Grant
- 1996-06-19 PL PL96324242A patent/PL184872B1/pl unknown
- 1996-06-19 SK SK1761-97A patent/SK176197A3/sk unknown
- 1996-06-19 SI SI9630768T patent/SI1082965T1/sl unknown
- 1996-06-19 BR BRPI9609414A patent/BRPI9609414B8/pt not_active IP Right Cessation
- 1996-06-19 AU AU63591/96A patent/AU696338B2/en not_active Expired
- 1996-06-19 CA CA2222455A patent/CA2222455C/en not_active Expired - Lifetime
- 1996-06-19 PT PT96922871T patent/PT833662E/pt unknown
- 1996-06-19 CN CNB961949732A patent/CN1146444C/zh not_active Expired - Lifetime
- 1996-06-19 KR KR1019970709651A patent/KR100425929B1/ko not_active IP Right Cessation
- 1996-06-19 TR TR97/01682T patent/TR199701682T1/xx unknown
- 1996-06-19 DE DE69637950T patent/DE69637950D1/de not_active Expired - Lifetime
- 1996-06-19 AT AT96922871T patent/ATE199831T1/de active
- 1996-06-19 NZ NZ312132A patent/NZ312132A/en not_active IP Right Cessation
- 1996-06-19 EA EA199700413A patent/EA199700413A1/ru unknown
- 1996-06-19 DE DE69612198T patent/DE69612198T3/de not_active Expired - Lifetime
- 1996-06-19 IL IL12258896A patent/IL122588A/en not_active IP Right Cessation
- 1996-06-19 AT AT00203874T patent/ATE433329T1/de active
- 1996-06-19 ES ES00203874T patent/ES2325301T3/es not_active Expired - Lifetime
- 1996-06-19 WO PCT/EP1996/002690 patent/WO1997000697A1/en active IP Right Grant
- 1996-06-19 ES ES96922871T patent/ES2157447T5/es not_active Expired - Lifetime
- 1996-06-19 JP JP50358197A patent/JP4850987B2/ja not_active Expired - Lifetime
- 1996-06-21 AR ARP960103253A patent/AR003006A1/es active IP Right Grant
- 1996-06-21 MA MA24292A patent/MA23918A1/fr unknown
- 1996-06-21 MY MYPI96002531A patent/MY114786A/en unknown
- 1996-06-21 PE PE1996000474A patent/PE11298A1/es not_active IP Right Cessation
- 1996-06-22 DZ DZ960099A patent/DZ2055A1/fr active
- 1996-06-22 EG EG57496A patent/EG25924A/xx active
- 1996-06-25 TW TW085107646A patent/TW467746B/zh not_active IP Right Cessation
-
1997
- 1997-12-19 OA OA70169A patent/OA10646A/en unknown
- 1997-12-22 NO NO19976035A patent/NO325169B1/no not_active IP Right Cessation
- 1997-12-23 BG BG102146A patent/BG62720B1/bg unknown
-
1998
- 1998-09-23 HK HK98110884A patent/HK1009764A1/xx not_active IP Right Cessation
- 1998-09-23 HK HK01106309.2A patent/HK1037516A1/xx not_active IP Right Cessation
-
2001
- 2001-06-19 GR GR20010400933T patent/GR3036088T3/el unknown
-
2002
- 2002-09-23 CY CY0200056A patent/CY2297B1/xx unknown
-
2008
- 2008-02-14 JP JP2008033301A patent/JP2008120833A/ja active Pending
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004501873A (ja) * | 2000-06-29 | 2004-01-22 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
JP2010163453A (ja) * | 2000-06-29 | 2010-07-29 | Glaxosmithkline Biologicals Sa | ワクチン組成物 |
JP4870895B2 (ja) * | 2000-06-29 | 2012-02-08 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
JP2012051943A (ja) * | 2001-04-03 | 2012-03-15 | Glaxosmithkline Biologicals Sa | ワクチン組成物 |
JP2006512406A (ja) * | 2002-11-01 | 2006-04-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原組成物 |
JP2010532985A (ja) * | 2007-07-10 | 2010-10-21 | サノフィ・パスツール | ヘモフィルス・インフルエンザb型菌用の培養培地 |
JP2012520849A (ja) * | 2009-03-19 | 2012-09-10 | インターベツト・インターナシヨナル・ベー・ベー | 動物の所定の群れに対して投与するためのワクチンのその場(insitu)構成 |
JP2012521402A (ja) * | 2009-03-24 | 2012-09-13 | ノバルティス アーゲー | アジュバント添加した髄膜炎菌h因子結合タンパク質 |
JP2014237696A (ja) * | 2009-03-24 | 2014-12-18 | ノバルティス アーゲー | アジュバント添加した髄膜炎菌h因子結合タンパク質 |
JP2016014049A (ja) * | 2009-03-24 | 2016-01-28 | ノバルティス アーゲー | アジュバント添加した髄膜炎菌h因子結合タンパク質 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4850987B2 (ja) | リン酸アルミニウム上に吸着したポリサッカライド結合抗原を含むワクチン組成物 | |
JP4233113B2 (ja) | 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン | |
CA2810326A1 (en) | Vaccine composition | |
US6756040B2 (en) | Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminum phosphate | |
US20030157129A1 (en) | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein | |
ES2224252T3 (es) | Composicion de vacuna que comprende fragmentos de la proteina de membrana externa de bordetella pertussis. | |
MXPA97010521A (en) | A composition of vaccines including an antigen conjugated of polysaccharid adsorbided in alumi phosphate | |
KR19990022680A (ko) | 폴리사카라이드 항원-담체 단백질 콘쥬게이트 및유리 담체단백질을 포함하는 백신 | |
SA96170157B1 (ar) | تركيب لقاح composition vaccine يشتمل على مولد مضاد متعدد سكريد مقترن antigen conjugated polsaccharide يتم امتزازه على فوسفات الألومنيوم aluminum phosphate | |
MXPA97009732A (en) | Vaccine comprising a conjugate of antigen depolisacarido protein carrier and protein carrier li |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070209 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071016 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20080115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110824 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110907 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110908 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20111020 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20141028 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |